Review ArticlesMetabolic Syndrome Is Associated With Ocular Hypertension and GlaucomaRoddy, Gavin W. MD, PhDAuthor Information Department of Ophthalmology, Mayo Clinic, Rochester, MN Funded by American Glaucoma Society, Mayo Foundation. Disclosure: The author declares no conflict of interest. Reprints: Gavin W. Roddy, MD, PhD, Department of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 (e-mail: email@example.com). Journal of Glaucoma: September 2020 - Volume 29 - Issue 9 - p 726-731 doi: 10.1097/IJG.0000000000001593 Buy SDC Metrics Abstract Glaucoma remains the world’s leading cause of irreversible blindness and though intraocular pressure (IOP) is the most prevalent risk factor and only reliable therapeutic target, a number of systemic disease associations have been reported. Metabolic syndrome (MetS) is a constellation of findings that includes systemic hypertension, abdominal obesity, glucose intolerance, and dyslipidemia. MetS is becoming increasingly common worldwide, with prevalence up to 40% in some countries. Not only is MetS a significant cause of morbidity, but it is also associated with an increase in all-cause mortality. Reports have been conflicting regarding the association of individual components of MetS, including systemic hypertension and diabetes, with elevated IOP or glaucoma. However, though limitations in the existing literature are present, current evidence suggests that MetS is associated with IOP as well as glaucoma. Additional studies are needed to clarify this association by incorporating additional metrics including assessment of central corneal thickness as well as optic nerve structure and function. Future studies are also needed to determine whether lifestyle modification or systemic treatment of MetS could reduce the incidence or progression of glaucoma. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.